OnKure Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | — | — | — |
| Research and development | $48.3M | $43.8M | $32.1M | $37.7M | $28.2M |
| Operating expenses | $63.0M | $54.4M | $36.9M | $53.8M | $39.8M |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M |
| Pretax income | — | — | -$77.4M | -$52.0M | -$39.8M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M | -$39.8M |
| Balance Sheet | |||||
| Cash and equivalents | $59.0M | $110.8M | $29.9M | $19.9M | $124.7M |
| Current assets | $60.8M | $113.0M | $33.8M | $106.4M | $153.7M |
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M |
| Current liabilities | $5.9M | $10.5M | $7.3M | $7.1M | $6.2M |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M |
| Stockholders' equity | $56.2M | $103.8M | -$101.8M | -$54.4M | $147.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M |
| Depreciation and amortization | $447,000 | $459,000 | $417,000 | $88,000 | $50,000 |
| Stock-based compensation | $11.6M | $4.5M | $199,000 | $4.3M | $3.9M |
| Capital expenditure | $46,000 | $52,000 | $246,000 | $346,000 | $198,000 |
| Free cash flow | -$51.9M | -$51.2M | -$34.8M | -$47.7M | -$38.2M |
| Share repurchases | — | — | $4.4M | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 40.4M · Free float 39.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.